Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), marketed under the brand name Egrifta by the Canadian company Theratechnologies. It occupies an unusual position in the peptide world: while most peptides discussed online are sold as research chemicals with little or no human trial data, tesamorelin is a fully approved prescription medicine that passed two multicenter phase 3 trials and received U.S. Food and Drug Administration approval in November 2010.

Chemically, tesamorelin is the full 44-amino-acid sequence of human GHRH(1-44) amide with one modification: a trans-3-hexenoyl group is attached to the N-terminal tyrosine. That small addition is the entire point of the molecule. Native GHRH is cleaved within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4), which snips the first two residues and destroys biological activity. The hexenoyl cap shields that cleavage site, giving tesamorelin enough metabolic stability to be a practical once-daily subcutaneous injection while preserving the receptor binding of the natural hormone.

The approved indication is deliberately narrow. Tesamorelin is indicated for the reduction of excess abdominal fat in adults living with HIV who have lipodystrophy. HIV-associated lipodystrophy is a metabolic complication in which fat redistributes away from the limbs and face and accumulates in the abdomen as visceral adipose tissue, the metabolically active fat that surrounds the internal organs. This pattern is associated with insulin resistance, dyslipidemia and cardiovascular risk, and it had no targeted pharmacological option before tesamorelin.

Two points about the label deserve emphasis because they are routinely lost in online summaries. First, the FDA label states that tesamorelin has not been shown to improve cardiovascular outcomes, only to reduce a fat compartment associated with risk. Second, it is not indicated for weight management of any kind. Visceral fat falls, but total body weight typically does not change meaningfully, because the drug redistributes rather than eliminates energy stores.

The product has been reformulated more than once since launch. The original Egrifta required refrigeration and a two-vial reconstitution. Egrifta SV, approved in 2019, simplified this to a single vial, and a later room-temperature-stable formulation reduced the cold-chain burden further. The active molecule is unchanged across these versions; only the presentation, diluent volume and storage requirements differ.

This guide is for educational purposes only. It is not medical advice and contains no recommended dose. Consult a qualified healthcare professional before considering any prescription medicine.

Tesamorelin is a GHRH receptor agonist. After subcutaneous injection it reaches the anterior pituitary and binds the same G-protein-coupled receptor that native hypothalamic GHRH uses. Receptor activation raises intracellular cyclic AMP in somatotroph cells, which triggers both the release of stored growth hormone and increased transcription of the GH gene. The downstream consequence is a rise in circulating growth hormone (GH), which acts on the liver and peripheral tissues to increase production of insulin-like growth factor 1 (IGF-1).

The mechanistic argument in favor of this approach, compared with injecting recombinant growth hormone directly, concerns physiological regulation. Tesamorelin acts one step upstream, at the pituitary, so the resulting GH output still moves through the body's normal control architecture. Pulsatility is broadly preserved rather than replaced by a flat pharmacological level, and negative feedback from somatostatin and from IGF-1 itself remains intact. In practice this means the pituitary retains some ability to limit the response, which is one reason the adverse effect profile of GHRH analogs differs from that of supraphysiological recombinant GH.

The pharmacokinetics are deliberately short. Reported elimination half-life after subcutaneous administration is roughly 26 minutes in healthy volunteers and around 38 minutes in people living with HIV, with peak plasma concentrations reached within about 15 minutes. This is a brief, sharp stimulus rather than a sustained one, which is precisely what the design intends: a transient GHRH signal that mimics a physiological pulse and then clears.

Why should this reduce visceral fat specifically? Growth hormone is lipolytic, and visceral adipose tissue is unusually responsive to it. VAT has a higher density of GH receptors and beta-adrenergic receptors than subcutaneous fat, along with high lipolytic turnover. GH activates hormone-sensitive lipase and suppresses lipoprotein lipase activity in adipocytes, tilting the balance toward fat mobilization. It also inhibits the enzyme 11-beta-hydroxysteroid dehydrogenase type 1, which regenerates active cortisol within adipose tissue and promotes visceral fat accumulation. People with HIV-associated lipodystrophy often show blunted GH secretion, so restoring the signal addresses a documented deficit rather than simply pushing a normal system harder.

The IGF-1 rise is the most reliable biomarker of pharmacological effect and is also the main reason for monitoring. In the pivotal trials, mean IGF-1 increased substantially, and the label advises periodic measurement because sustained elevation above the normal range raises theoretical concerns about cell proliferation. Clinicians typically track both IGF-1 and glucose parameters during treatment.

The foundational evidence is Falutz et al., New England Journal of Medicine, 2007 (PMID 18057338), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial in adults living with HIV who had excess abdominal fat. Participants received daily subcutaneous tesamorelin or placebo for 26 weeks. The primary endpoint was the percentage change in visceral adipose tissue measured by computed tomography at the L4-L5 level, which is the reference standard for quantifying this fat compartment and far more informative than waist circumference or bioimpedance.

The result: visceral adipose tissue fell by approximately 15 percent in the tesamorelin group while rising slightly in the placebo group, giving a net treatment difference in the region of 20 percent. Waist circumference decreased modestly, triglycerides improved, and the ratio of total to HDL cholesterol shifted favorably. IGF-1 rose sharply, confirming target engagement. Importantly, subcutaneous fat was largely spared, which matters in a population where subcutaneous fat loss in the face and limbs is itself a clinical problem.

The follow-up analysis, Falutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010 (PMID 20101189), pooled the two phase 3 trials and extended observation to 52 weeks with re-randomization. This study produced the single most practically important finding in the tesamorelin literature: participants who had responded during the first 26 weeks and were then switched to placebo regained visceral fat, drifting back toward baseline, whereas those who continued treatment broadly maintained their reduction.

That reversibility reframes how the drug should be understood. Tesamorelin does not remodel adipose tissue in a way that persists after withdrawal. It maintains a pharmacological state, and when the stimulus stops, physiology returns to its prior set point. The comparison is closer to an antihypertensive than to a course of antibiotics. This is also why the label directs clinicians to assess response at around six months and to consider discontinuation if no meaningful benefit has occurred, since continued exposure without benefit carries risk without reward.

Two limitations should temper interpretation. The trials enrolled a specific population, adults with HIV-associated lipodystrophy, whose blunted GH axis may make them unusually responsive. Extrapolating the effect size to metabolically healthy people is not supported by these data. And the endpoints were surrogate measures: CT-quantified fat and lipid panels, not heart attacks, strokes or mortality. Visceral fat is strongly associated with cardiovascular risk, but reducing a risk marker pharmacologically does not automatically reduce events, and the label says so explicitly.

Because visceral fat and hepatic fat are metabolically linked, researchers examined whether the drug's effect extended to the liver. Stanley et al., JAMA, 2014 (PMID 25038357) randomized adults with HIV and abdominal fat accumulation to tesamorelin or placebo for six months, using magnetic resonance spectroscopy to quantify hepatic fat fraction, a far more precise technique than ultrasound or liver enzyme measurement.

Liver fat decreased in the tesamorelin group and increased slightly on placebo, producing a statistically significant between-group difference. Visceral fat fell in parallel, as expected. This was a meaningful finding because non-alcoholic fatty liver disease is common in people living with HIV, is difficult to treat, and had essentially no approved pharmacological option at the time. Later work extended observation to twelve months and examined markers of liver inflammation and fibrosis, but tesamorelin has never been approved for fatty liver disease in any jurisdiction, and clinicians treating NAFLD outside the HIV context have far better-established options. Readers comparing metabolic approaches may also want to review the very different mechanism of semaglutide, a GLP-1 receptor agonist with large outcome trials behind it.

The cognitive research is more preliminary and more frequently misrepresented online. Baker et al., Archives of Neurology, 2012 (PMID 22869065) conducted a randomized, double-blind, placebo-controlled trial of GHRH administered for 20 weeks to older adults, including both cognitively healthy participants and participants with mild cognitive impairment. The rationale was that GH and IGF-1 decline markedly with age and both influence hippocampal function, synaptic plasticity and neurotransmitter systems.

The trial reported a favorable effect on executive function, the domain covering planning, mental flexibility and set-shifting, with a weaker signal on verbal memory. IGF-1 rose substantially, and the authors also observed a modest increase in fasting insulin, consistent with the known glucose effects of GH axis stimulation.

What this study does not show is equally important. It was a single trial of modest size and 20 weeks duration, measuring performance on cognitive test batteries rather than clinical outcomes. It did not demonstrate prevention of dementia, slowing of Alzheimer's disease, or any durable benefit after treatment ended. Whether a change on an executive function composite translates into anything a person would notice in daily life remains unanswered. Treating this trial as evidence that tesamorelin is a cognitive enhancer misreads exploratory neuroscience as established therapy.

Tesamorelin is regularly grouped with other growth-hormone-related peptides, but the four most discussed compounds differ in mechanism, regulatory standing and, above all, in the quality of human evidence behind them. The table below summarizes the key distinctions.

The central distinction is mechanistic. Tesamorelin, CJC-1295 and sermorelin are all GHRH receptor agonists acting on the same pituitary target, differing mainly in how long they survive in circulation. Ipamorelin works through a completely different receptor, the ghrelin receptor, and is a growth hormone secretagogue rather than a GHRH analog. That difference in pathway is the theoretical basis for the popular practice of combining the two classes.

The second distinction is the one that matters most for anyone evaluating claims. Tesamorelin has been tested in hundreds of randomized participants with imaging-based endpoints and regulatory scrutiny of the full dataset. The other three have no comparable body composition evidence in humans. Absence of trials is not evidence that they do not work, but it does mean that any specific claim about how much visceral fat they remove is extrapolation rather than measurement.

A third practical difference is duration of exposure. Tesamorelin and sermorelin produce short, pulse-like signals. CJC-1295 with DAC produces days-long elevation of GH and IGF-1, which departs substantially from normal physiology and undermines the pulsatility argument that makes GHRH analogs attractive in the first place. For broader context on how these compounds are positioned relative to other approaches, see our overview of peptides studied for fat loss.

Tesamorelin has developed a following well outside its approved indication, primarily among people seeking abdominal fat reduction, improved body composition or anti-aging effects. Assessing that use honestly requires separating what has been demonstrated from what has been inferred.

What is established: in adults living with HIV who have lipodystrophy, daily tesamorelin reduces CT-measured visceral adipose tissue by a clinically meaningful margin over 26 weeks, largely spares subcutaneous fat, improves triglycerides, reduces hepatic fat in those with fatty liver, and reverses when discontinued. This rests on adequately powered randomized trials with objective imaging endpoints.

What is inferred but not demonstrated: that the same magnitude of effect occurs in people without HIV. This is the central gap. Participants in the pivotal trials had a blunted growth hormone axis as part of their condition, and restoring a deficient signal is pharmacologically different from amplifying an intact one. A person with normal GH secretion and normal pituitary feedback may respond considerably less, because the negative feedback loops that preserve safety also limit the achievable increase. There is no adequately powered randomized trial of tesamorelin for visceral fat reduction in a metabolically healthy, HIV-negative population, and stating otherwise is not supported by the literature.

What is not supported at all: claims that tesamorelin builds muscle, reverses aging, improves athletic performance, or produces substantial weight loss. The trials measured body weight and found little change. Growth hormone's effect on lean mass in adults with normal pituitary function is modest, and much of the early gain reported with GH-axis interventions reflects fluid retention rather than contractile tissue. The cognitive findings from Baker et al. are genuinely interesting but remain a single exploratory trial in older adults, not a basis for use.

Active research has explored tesamorelin in non-HIV metabolic fatty liver disease, in general abdominal obesity, and in age-related cognitive decline. Some of this work is ongoing. Until randomized results in those populations are published and replicated, the responsible position is that the drug is well characterized in one clinical context and largely uncharacterized outside it.

One further consideration applies to anyone subject to drug testing. Tesamorelin and all other GHRH analogs and growth hormone secretagogues are prohibited at all times under category S2 of the World Anti-Doping Agency list. This applies in and out of competition, and detection methods for GHRH analogs exist.

Because tesamorelin went through formal regulatory review, its safety profile is documented from controlled trials rather than anecdote. That is a genuine advantage over unapproved peptides, where adverse events are simply never systematically collected.

The most common adverse reactions in the phase 3 program were injection site reactions, including redness, itching, pain, irritation and bruising. These were frequent, generally mild, and a leading reason for discontinuation. Arthralgia and myalgia were also common, consistent with the known effects of growth hormone on connective tissue. Peripheral edema reflects the sodium and fluid retention that GH promotes. Some participants reported paresthesia, hypoesthesia or carpal tunnel-like symptoms, which are classic GH-axis effects caused by soft tissue swelling compressing nerves in confined spaces. Nausea, vomiting, rash and muscle pain were reported less often.

Two systemic issues require laboratory monitoring rather than symptom watching. The first is glucose metabolism. Growth hormone is a counter-regulatory hormone that opposes insulin action, and raising GH can worsen insulin sensitivity, increase fasting glucose and HbA1c, and in susceptible individuals precipitate diabetes. The label advises monitoring glucose before and during treatment, with particular caution in anyone who already has prediabetes or diabetes. The second is IGF-1 elevation. Sustained IGF-1 above the normal reference range is the main reason for periodic measurement, since IGF-1 is a mitogenic signal.

The contraindications in the FDA labeling are specific. Tesamorelin is contraindicated in people with disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma, because the drug requires an intact pituitary to work and may be inappropriate in that setting. It is contraindicated in active malignancy, given the theoretical risk that GH and IGF-1 stimulation could promote growth of existing neoplastic tissue. Any preexisting malignancy should be inactive and its treatment complete before consideration. It is contraindicated in pregnancy, where the fat reduction offers no benefit and fetal exposure to elevated IGF-1 is not justified, and in anyone with known hypersensitivity to tesamorelin or to mannitol, a component of the formulation.

Additional cautions include diabetic retinopathy, where GH axis stimulation may aggravate the condition, and fluid retention in people with cardiac or renal compromise. Hypersensitivity reactions including pruritus, urticaria and rash have been reported and warrant discontinuation.

None of this constitutes medical advice. Tesamorelin is a prescription medicine whose risk-benefit balance depends on individual history, comorbidities and concurrent medications, and that assessment can only be made by a qualified clinician.

Tesamorelin is supplied as a lyophilized (freeze-dried) powder in a sealed vial and must be reconstituted with a sterile diluent before use. This is standard for peptide drugs, because peptides in aqueous solution are far less stable than in dry form and would not survive a normal shelf life.

The specific procedure depends entirely on the formulation, which is why generic instructions found online are unreliable. The original Egrifta presentation required refrigeration and reconstitution across two vials. Egrifta SV consolidated this into a single vial reconstituted with a small volume of sterile water for injection. The most recent room-temperature-stable formulation changed both the diluent volume and the storage requirements again. The only authoritative source for a given product is the prescribing information and instructions for use that accompany that specific package. Diluent type, volume, storage temperature and in-use stability all differ between versions.

Some general principles apply across peptide reconstitution regardless of product. The diluent should be introduced slowly down the inner wall of the vial rather than injected directly onto the powder cake, because peptides are vulnerable to shear stress at the air-liquid interface. The vial should be swirled gently or rolled, never shaken, since agitation causes aggregation and denaturation that reduce potency. The reconstituted solution should be clear; cloudiness, visible particles or discoloration indicate the vial should not be used. Our step-by-step walkthrough of peptide reconstitution covers the general technique in more detail.

For concentration arithmetic, readers can use our tesamorelin reconstitution calculator, which converts between vial strength, diluent volume and the resulting concentration. The tool performs arithmetic only. It does not recommend a dose, and this article does not state one. The appropriate dose, frequency, injection technique and treatment duration are determined by the prescribing information and by the clinician who prescribes the medicine, taking into account the individual patient.

Once reconstituted, in-use stability is limited and formulation-specific. Some presentations require immediate use, others permit brief refrigerated storage. Exceeding the stated window risks both loss of potency and microbial contamination, since most single-use presentations contain no preservative. Light exposure and freezing should both be avoided unless the labeling states otherwise.

In the United States, tesamorelin is a prescription-only medicine regulated by the FDA. It is legal to possess and use when prescribed by a licensed clinician and dispensed by a licensed pharmacy. It is not a controlled substance, so possession with a valid prescription carries no special restrictions, but it is also not a dietary supplement and cannot lawfully be marketed as one.

Availability outside the United States varies considerably, and approval in one country does not imply approval in another. Tesamorelin is not available as an approved medicine throughout the European Union, and readers should verify the position with their own national regulator rather than assuming that FDA approval confers international legality. Importing a prescription medicine for personal use is restricted or prohibited in many jurisdictions regardless of where it was purchased.

A separate and important category is research-grade tesamorelin sold online under a research use only designation. These products are not FDA-approved medicines. They are not manufactured under the same pharmaceutical quality systems, are not subject to batch release testing by a regulator, and carry no guarantee of identity, purity, sterility or accurate labeled quantity. Independent testing of the research peptide market has repeatedly found products that are underdosed, contaminated, or that contain a different compound entirely. The FDA has issued warning letters to companies marketing unapproved peptide products for human use. Purchasing these materials for self-administration sits outside any regulatory protection, and the legal position varies by country.

On cost, we will not publish a figure. Branded tesamorelin is an expensive specialty medicine, list prices differ substantially between formulations, countries and payers, and insurance coverage for the HIV lipodystrophy indication changes over time. Any specific number quoted in an article would be outdated quickly and potentially misleading. Anyone with a genuine clinical need should obtain current pricing from their pharmacy, their insurer, or the manufacturer's patient support program, all of which reflect actual acquisition cost far better than a third-party estimate. For research-grade material, check the current price on the supplier's own site.

Medical disclaimer: this article is provided for educational purposes only and does not constitute medical advice, a recommendation, or an endorsement of any use of tesamorelin. It contains no dosing guidance by design. Tesamorelin is a prescription medicine with defined contraindications and monitoring requirements. Consult a qualified healthcare professional before considering it, and do not use any peptide product to self-treat a medical condition.